Home / Fact sheets / Population fact sheet

Country fact sheet: Sweden

Population

- Total population: 9 923 085
- Female population: 4 960 220
- Male population: 4 962 865
The World Bank (2016)

Health Expenditure

- Total per capita (US$): 5 600.1
- Out-of-pocket (% of total expenditure on health): 15.2
World Health Organization (2015)

Human Development Index

- HDI: 0.913
- Category: Very high
UNDP Human Development Report (2015)

Geography

Life Expectancy at Birth

- Total population (years): 82.2
- Female population (years): 84.1
- Male population (years): 80.4
The World Bank (2016)

Cancer Burden

- Overall cancer incidence (rate per 100 000 persons per year): 294.7
- Overall cancer mortality (rate per 100 000 persons per year): 86.8
- Most common cancer site by incidence for females (rate per 100 000 persons per year): Breast (89.8)
- Most common cancer site by mortality for females (rate per 100 000 persons per year): Lung (14.8)
- Most common cancer site by incidence for males (rate per 100 000 persons per year): Prostate (103.0)
- Most common cancer site by mortality for males (rate per 100 000 persons per year): Prostate (15.0)
- GLOBOCAN 2018 population fact sheet
GLOBOCAN (2018)

Screening programmes

       

BREAST CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2016
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2013
Source of data: Report (EU Report 2017)

Screening protocol

Year published/updated:
Screening test used: 1
Target age (min-max) and screening interval [months] for each test: Mammography
(40-74 years / [18 months] )

Programme status and organization

Dedicated person/team to coordinate the programme:
Budget line for screening programme:
Documented cancer screening policy:
Nature of documentation of the policy: Official recommendation
Program introduction was preceded by a pilot:
Year program was initiated: 1986
Screening tests provided free of charge:
Diagnostic tests provided free of charge:
Treatment services provided free of charge:

Information system/Data collection

Data type collected by the programme: Individual
The information system collects data outside the program (opportunistic screening/private sector):
Cancer screening registries covering the entire country/region:
Cancer screening data is linked with Population-based cancer registry:

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: Population register
Annual target for screening coverage:
Invitations to eligible population: For the entire target population
Method of invitation: letter
Screen positive individuals actively invited for further assessment:
Individuals with a precancer or cancer diagnosis actively contacted:
Program collects data on the treatment of precancer/cancers:

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA:
Responsible person/team for QA:
Documented performance indicators and their reference standards to assess the programme:
Evaluation reports are prepared and published:

Cancer Screening programme status

Nature of cancer screening programme: Population-based
Current status of implementation (applicable only for population-based programmes): Roll-out completed
Cancer screening programme population based for selected populations:

Performance indicators

Target age and regional limitation if applicable: 50-69 years for Stockholm
Invitation coverage (%): 95.6
Examination coverage (%): 70
Participation rate (%): 73.2
Completeness of data related to screening results (%): 100
Completeness of data related to further assessment results (%): 96.7
Further assessment rate (%): 2.4
Further assessment participation rate (%): 98.9
Detection rate of CIS and invasive (x 1000): 6.12
Detection rate of invasive cancer (x 1000): 0.9
Positive predictive value of further assessment to detect CIS and invasive (%): 26.0
Proportion of total carcinomas which are CIS (%): 14.7
Benign surgical biopsy rate (x 1000): 0.5
More quantitative data (Norra: 2013)
More quantitative data (Stockholm: 2013)
More quantitative data (Sydöstra: 2013)
More quantitative data (Södra: 2013)
More quantitative data (Uppsala Örebro: 2013)
More quantitative data (Västra Götaland: 2013)



CERVICAL CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2016
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2013
Source of data: Report (EU Report 2017)

Screening protocol

Year published/updated:
Screening test used: 1
Target age (min-max) and screening interval [months] for each test: Cytology
(23-60 years / [36 months] )
Triaging test used: HPV
"screen and treat" included in the protocol:

Programme status and organization

Dedicated person/team to coordinate the programme:
Budget line for screening programme:
Documented cancer screening policy:
Nature of documentation of the policy: Official recommendation
Program introduction was preceded by a pilot:
Year program was initiated: 1967
Screening tests provided free of charge:
Diagnostic tests provided free of charge:
Treatment services provided free of charge:

Information system/Data collection

Data type collected by the programme: Individual
The information system collects data outside the program (opportunistic screening/private sector):
Cancer screening registries covering the entire country/region:
Cancer screening data is linked with population-based cancer registry:

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: Population register
Annual target for screening coverage:
Invitations to eligible population: Excluding those covered by opportunistic screening
Screening kit included with the invitation:
Method of invitation: letter
Screen positive individuals actively invited for further assessment:
Individuals with a precancer or cancer diagnosis actively contacted:
Program collects data on the treatment of precancer/cancers:

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA:
Responsible person/team for QA:
Documented performance indicators and their reference standards to assess the programme:
Evaluation reports are prepared and published:

Cancer Screening programme status

Nature of cancer screening programme: Population-based
Current status of implementation: Roll-out completed
Cancer screening programme population based for selected populations/regions:

Performance indicators

Target age and regional limitation if applicable: 30-59 years
Invitation coverage (%): 131.3
Examination coverage (invitation cohort) (%): 70.6
Examination coverage (tests in the index-year) (%): 87.0
Participation rate (%): 52.7
Completeness of data related to screening test results (%): 100
Completeness of data related to further assessment results (%): 33.9
Colposcopy referral rate (%): 3.8
Colposcopy participation rate (%): 59.5
Detection rate of CIN2+ (x 1000): 6.75
Detection rate of CIN3+ (x 1000): 4.28
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000): 30.1
Positive Predictive Value of CIN3+ (x 1000): 30.1
More quantitative data (2013)



COLORECTAL CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2013
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2013
Source of data: No source

Screening protocol

Year published/updated:
Screening test used: 1
Target age (min-max) and screening interval [months] for each test: gFOBT: (60-69 years / [24 months] )

Programme status and organization

Dedicated person/team to coordinate the programme:
Budget line for screening programme:
Documented cancer screening policy:
Nature of documentation of the policy: Official recommendation
Program introduction was preceded by a pilot:
Year program was initiated: 2008
Screening tests provided free of charge:
Diagnostic tests provided free of charge:
Treatment services provided free of charge:

Information system/Data collection

Data type collected by the programme: Individual
The information system collects data outside the program (opportunistic screening/private sector):
Cancer screening registries covering the entire country/region:
Cancer screening data is linked with population-based cancer registry: PBCR exists but not linked

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: Population register
Annual target for screening coverage:
Invitations to eligible population: For the entire target population
Method of invitation: letter
Screen positive individuals actively invited for further assessment:
Individuals with a precancer or cancer diagnosis actively contacted:
Program collects data on the treatment of precancer/cancers:

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA:
Responsible person/team for QA:
Documented performance indicators and their reference standards to assess the programme:
Evaluation reports are prepared and published:

Cancer Screening programme status

Nature of cancer screening programme: Population-based
Current status of implementation (applicable only for population-based programmes): Roll-out completed
Cancer screening programme population based for selected populations:

Performance indicators

FIT gFOBT sigmoidoscopy Colonoscopy
Target age and regional limitation if applicable: 50-74
Invitation coverage (%): 104.2
Examination coverage (%): 62.7
Participation rate (%): 60.2
Completeness of data related to screening results (%): 92.4
Completeness of data related to information about attendance to colonoscopy assessment (%): 100.0
Completeness of data related to histology result (%): 100.0
Screen positivity (indication for follow-up colonoscopy) rate (%) : 3.3
Follow-up colonoscopy participation rate (%): 89.5
Completion rate follow-up colonoscopy (%):
Detection rate of adenomas (x 1000): 6.9
Detection rate of advanced adenomas (x 1000): 2.4
Detection rate of colorectal cancers (x 1000): 0.9
Positive Predictive Value of further assessment to detect adenomas (%): 23.8
Positive Predictive Value of further assessment to detect advanced adenomas (%): 8.5
Positive Predictive Value of further assessment to detect colorectal cancers (%): 3.3
More quantitative data for gFOBT (Male - Stockholm: 2013)
More quantitative data for gFOBT (Women - Stockholm: 2013)